SARS-CoV-2 seroprevalence and associated factors among migrants with a vocation for permanence, Bucaramanga, Colombia
DOI:
https://doi.org/10.15649/cuidarte.2657Keywords:
SARS-CoV-2, Seroepidemiologic Studies, Transients and MigrantsAbstract
Introduction:There are few reports assessing anti-SARS-CoV-2 seroprevalence in the migrant population in the world. These studies help to understand the exposure of populations to the virus to take actions to reduce the impact of SARS-CoV-2 infection. Objetive: To determine the anti-SARS-CoV-2 seroprevalence in migrants with a vocation for permanence in Bucaramanga and to identify factors associated with previous SARS-CoV-2 infection. Materials and Methods:Analytical cross-sectional study using consecutive sampling, which included adult migrants in Bucaramanga in February 2021. Surveys were conducted, and chemiluminescent immunoassays were performed to detect IgM and IgG antibodies to SARS-CoV-2 in serum samples. Prevalence ratios (PR) were estimated using a log-binomial regression model. Results:The study enrolled 462 participants. IgM seroprevalence was 11.7% (95% CI 9.1–14.9), IgG seroprevalence was 32.9% (95% CI 28.8–37.3), and IgM or IgG seroprevalence was 36.1% (95% CI 31.9–40.6). Contact with a confirmed case of COVID-19 (PR:1.54; 95% CI 1.04-2.29) or suspected case (PR:1.56; 95% CI 1.13–2.16); living with six or more people (PR: 1.52; 95% CI 1.05–2.20); stay in Colombia ≥ 2 years (PR:1.43; 95% CI 1.11–1.92), and presence of symptoms (PR:1.62; 95%CI 1.26–2.10) were some factors associated with higher IgG seroprevalence. Discussion: In Bucaramanga, SARS-CoV-2 seroprevalence among migrants was similar to the seroprevalences of migrants in Kuwait but lower than migrants in Paris and Singapore. Conclusions: The anti-SARS-CoV-2 seroprevalence among migrants with a vocation for permanence was similar to that reported among residents of Bucaramanga. Contact with suspected or confirmed COVID-19 cases and crowded conditions were some of the factors associated with seroprevalence.
How to cite this article: Martínez-Vega Ruth Aralí, Bolívar-Grimaldos Alix, Rincón-Orozco Bladimiro. Seroprevalencia de SARS-CoV-2 y factores asociados en migrantes con vocación de permanencia, Bucaramanga, Colombia. Revista Cuidarte. 2022;13(3):e2657. http://dx.doi.org/10.15649/cuidarte.2657
References
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5:536-44.https://doi.org/10.1038/s41564-020-0695-z
WHO (COVID-19). World Health Organization. WHO. 2021. https://covid19.who.int/region/amro/country/co
Minsalud, Cluster Salud Colombia, OPS. Casos de COVID-19 de población migrante y refugiados venezolana en Colombia, corte 30 de Junio, 2020. PAHO. 2020. https://www.paho.org/es/documentos/infografia-casos-covid-19-poblacion-migrante-refugiados-venezolana-colombia-corte-30
Orcutt M, Patel P, Burns R, Hiam L, Aldridge R, Devakumar D, et al. Global call to action for inclusion of migrants and refugees in the COVID-19 response. Lancet. 2020; 395:1482-83. https://doi.org/10.1016/S0140-6736(20)30971-5
Hargreaves S, Zenner D, Wickramage K, Deal A, Hayward SE. Targeting COVID-19 interventions towards migrants in humanitarian settings. Lancet Infect Dis. 2020; 20:645-46. https://doi.org/10.1016/S1473-3099(20)30292-9
Daniels JP. Venezuelan migrants "struggling to survive" amid COVID-19. Lancet. 2020; 395: 1023. https://doi.org/10.1016/S0140-6736(20)30718-2
Organización de los Estados Americanos. Informe de situación diciembre 2020. Crisis de migrantes y refugiados venezolanos. 2020. https://www.oas.org/fpdb/press/OEA_Dic20-crisis-de-migrantes-y-refugiados-venezolanos-informe-de-situacion.pdf
Alali WQ, Bastaki H, Longenecker JC, Aljunid SM, AlSeaidan M, Chehadeh W, et al. Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait. J Travel Med. 2021; 28: 223. https://doi.org/10.1093/jtm/taaa223
Roederer T, Mollo B, Vincent C, Nikolay B, Llosa AE, Nesbitt R, et al. Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study. Lancet Public Health. 2021; 6: 202-209. . https://doi.org/10.1016/S2468-2667(21)00001-3
Tan IB, Tan C, Hsu LY, Dan YY, Aw A, Cook AR, et al. Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore. JAMA. 2021; 325: 584-85. https://doi.org/10.1001/jama.2020.24071
Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020; 58: 1081-88.https://doi.org/10.1515/cclm-2020-0443
Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6: 13652. https://doi.org/10.1016/j.jcv.2020.104413
Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 2020; 128:104413.
https://doi.org/10.1016/j.jcv.2020.104413
Valdivia A, Torres I, Latorre V, Francés-Gómez C, Albert E, Gozalbo-Rovira R, et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021; 40: 485-94. https://doi.org/10.1007/s10096-020-04128-8
Sempos CT, Tian L. Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error. Am J Epidemiol. 2021;190: 109-15. https://doi.org/10.1093/aje/kwaa174
Martinez-Vega R, Bolívar-Grimaldos A, Rincon B. Seroprevalencia de SARS-CoV-2 y factores asociados en migrantes con vocación de permanencia, Bucaramanga, Colombia. Mendeley Data, V1. 2022. https://doi.org/10.17632/cgdszwgbwf.1
Valdivia A, Torres I, Huntley D, Alcaraz MJ, Albert E, Solano de la Asunción C, et al. Caveats in interpreting SARS-CoV-2 IgM+ /IgG- antibody profile in asymptomatic health care workers. J Med Virol. 2021; 93: 634-36. https://doi.org/10.1002/jmv.26400
Clapham HE, Chia WN, Tan LWL, Kumar V, Lim JM, Shankar N, et al.Contrasting SARS-CoV-2 epidemics in Singapore: cohort studies in migrant workers and the general population. Int J Infect Dis. 2022; 115: 72-78. https://doi.org/10.1016/j.ijid.2021.11.043
Hasan T, Thach PN, Anh NT, Hien LTT, An NTM, Thuy DT, et al.The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam. IJID Reg. 2022; 2:137-140. https://doi.org/10.1016/j.ijregi.2021.12.001
Warszawski J, Meyer L, Franck JE, Rahib D, Lydié N, Gosselin A, et al. Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort-EPICOV. PLoS One. 2022. 25;17(5): e0267725. https://doi.org/10.1371/journal.pone.0267725
Al-Abri, S. S., Al-Wahaibi, A., Al-Kindi, H., Kurup, P. J., Al-Maqbali, A., Al-Mayahi, Z., et al. Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys. Int J Infect Dis. 2021;112: 269-277. https://doi.org/10.1016/j.ijid.2021.09.062
Instituto Nacional de Salud & Grupo Colaborativo Estudio País. . Seroprevalencia de SARS-CoV-2 durante la epidemia en Colombia: Estudio país (Reporte Preliminar No 5: Resultados globales Leticia, Barranquilla, Medellín, Bucaramanga, Cúcuta, Villavicencio, Cali, Bogotá́, Ipiales, Guapí). Bogotá. Instituto Nacional de Salud. 2021. https://www.ins.gov.co/BibliotecaDigital/Seroprevalencia-estudio-colombia.pdf
Colmenares-Mejía CC, Serrano-Díaz N, Quintero-Lesmes DC, Meneses L, Salazar Acosta I, Idrovo ÁJ, et al. Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia. Int J Environ Res Public Health. 2021. 15;18(8):4172. https://doi.org/10.3390/ijerph18084172
Vengesai A, Midzi H, Kasambala M, Mutandadzi H, Mduluza-Jokonya TL, Rusakaniko S, et al. A systematic and meta-analysis review on the diagnostic accuracy of antibodies in the serological diagnosis of COVID-19. Syst Rev. 2021. 26;10(1):155. https://doi.org/10.1186/s13643-021-01689-3
Published
How to Cite
Issue
Section
Categories
Altmetrics
Downloads
License
Journal Cuidarte, scientific publication of open access, is licensed under a Creative Commons Attribution (CC BY-NC), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Any other form of use such as reproduction, transformation, public communication or distribution, for profit, requires the prior authorization of the University of Santander UDES.
The names and e-mail addresses entered in the Journal Cuidarte will be used exclusively for the purposes stated by this magazine and will not be available for any other purpose or other person.
The articles published in the Journal Cuidarte represent the criteria of their authors and do not necessarily constitute the official opinion of the University of Santander UDES.
